Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Time course transcriptomic analysis of human melanoma A375 cells dying of immunogenic or non immunogenic apoptosis

ABSTRACT: Time course transcriptomic analysis of human melanoma A375 cells dying of immunogenic or non immunogenic apoptosis

PROVIDER: PRJNA685849 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13263700.fastq.gz	Fastqsanger.gz
	SRR13263800.fastq.gz	Fastqsanger.gz
	SRR13263701.fastq.gz	Fastqsanger.gz
	SRR13263801.fastq.gz	Fastqsanger.gz
	SRR13263702.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 156

Similar Datasets

Time course transcriptomic analysis of human melanoma A375 cells dying of immunogenic or non immunogenic apoptosis

Project description:We set out to investigate the transcriptional profile of cancer cells responding to mitoxantrone (MTX) or hypericin-based photodynamic therapy (Hyp-PDT), as prototypes of immunogenic treatments compared to cisplatin (CDDP), considered a poorly immunogenic chemotherapeutic. We isolated the bulk-RNA of the treated cells, at 0 hr (untreated) and 4 hr (pre-apoptotic), 10 hr (early apoptotic) and 20 hr (late apoptotic) post-treatment, and compared it to their respective time-matched untreated controls. Differential gene expression analysis revealed that MTX and Hyp-PDT significantly upregulated the transcription of several genes as early as 4 hr post-treatment, whereas responses to CDDP treatment occurred mainly at the later time points and were associated with a predominant transcript downregulation. Bioinformatics analyses showed pathways relative to chemokine signaling and inflammation as significantly associated selectively to cells dying in an immunogenic fashion.

2020-12-17 | GSE163377 | GEO

Gene expression of the A375 melanoma cell line treated with RAF inhibitors Vemurafenib and time-course with EGF stimulation during Vemurafenib RAF inhibitor treatment alone or with the MEK inhibitor Cobimetinib

Project description:We treated for 24 hours the BRAF-V600E melanoma cell line A375 with 7 doses of the RAF inhibitor Vemurafenib and, in a second experimental desing, we treated for 24 hours the BRAF-V600E melanoma cell line A375 with Vemurafenib (1 uM) alone or in combination with the MEK inhibitor Cobimetinib (1 uM) and subsequently stimulated with EGF in a time-course of 7 time points for up to 8 hours (0, 0.5, 1, 2, 3, 4, 8 hours).

2020-10-19 | GSE127988 | GEO

Circadian time course

Project description:Circadian time course

| PRJNA98585 | ENA

Immunogenic clearance combined with programmed cell death protein-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8+ T cell

Project description:Inducing immunogenic clearance enhances the phagocytosis of dying cancer cells and activates antigen-presenting cells, facilitating the immune system against cancer. This approach can potentially generate robust systemic antitumor immune responses and increase tumor responsiveness to anti-programmed cell death protein 1 (αPD-1) therapy. However, the precise mechanisms underlying this antitumor response induced by immunogenic clearance remain unclear. We used single cell RNA sequencing (scRNA-seq) to understand the underlying mechanism of the therapeutic strategy of immunogenic clearance.

2024-11-29 | GSE282150 | GEO

Kidney development time course

Project description:Kidney development time course

| PRJNA91337 | ENA

Analysis of gene expression profiles of human melanoma A375 cells with or without CD10 overexpression

Project description:Analysis of effect of CD10 in melanoma at gene expression level. The hypothesis tested in the present study was that CD10 promotes melanoma tumor progression. Results provide important information of the significant gene expression change between CD10-transfected and mock-transfected A375 cells, such as significantly increased genes included those related to anti-apoptosis, angiogenesis and cell proliferation. Total RNA obtained from CD10-transfected A375 melanoma cells was that from compared to mock-transfected A375 cells.

2014-10-18 | E-GEOD-62464 | biostudies-arrayexpress

gene-expression profiling between UBE2S knock down A375 cells and control A375 cells

Project description:investigate the gene expression change between UBE2S konck down A375 cells mediated by Lentivirus and control A375 cells.

2018-06-19 | GSE115922 | GEO

SmallRNAome profile of melanoma cell lines A375 and A375-BIR (BIR-BRAF INHIBITOR RESISTANT) during dabrafenib treatment

Project description:To analyse smallRNA expression differences between A375 and A375-BIR during the treatment with dabrafenib (DAB)

2024-05-03 | GSE165335 | GEO

Transcriptome profile of melanoma cell lines A375 and A375-BIR (BIR-BRAF INHIBITOR RESISTANT) during dabrafenib treatment

Project description:To analyse gene expression differences between A375 and A375-BIR during the treatment with dabrafenib (DAB)

2022-08-29 | GSE165334 | GEO

Mouse kidney endotoxin time course

Project description:Mouse kidney endotoxin time course